SEC Comment Letter 0000000000-23-012904 to FENNEC PHARMACEUTICALS INC. (FENC) (CIK 0001211583) (FENC)
FENNEC PHARMACEUTICALS INC. (FENC) (CIK 0001211583)
Date: Nov. 28, 2023 · CIK: 0001211583 · Accession: 0000000000-23-012904
AI Filing Summary & Sentiment
File numbers found in text: 333-275452
Letter
United States securities and exchange commission logo November 28, 2023 Robert Andrade Chief Financial Officer Fennec Pharmaceuticals Inc. PO Box 13628, 68 TW Alexander Drive Research Triangle Park, NC 27709 Re:Fennec Pharmaceuticals Inc. Registration Statement on Form S-3 Filed November 9, 2023 File No. 333-275452 Dear Robert Andrade: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Garrett Sleichter
Show Raw Text
United States securities and exchange commission logo
November 28, 2023
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
PO Box 13628, 68 TW Alexander Drive
Research Triangle Park, NC 27709
Re:Fennec Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed November 9, 2023
File No. 333-275452
Dear Robert Andrade:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Garrett Sleichter